Synonyms: (4"R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3"-[(4'-chloro[l,1'-biphenyl]-4-yl)methyl]vancomycin diphosphate; LY-333328
Molecular Formula: C86H97Cl3N10O26 · 2H3PO4
Molecular Weight: 1989.09
Linear Structural Formula: C86H97Cl3N10O26 · 2H3PO4
Purity: >=97% (HPLC)
Storage: -20C
Biochem Physiol Actions: Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and organisms resistant to vancomycin and other antibiotics such as linezolid and daptomycin. Oritavancin has multiple mechanisms of action, including inhibition of transglycosylation, inhibition of transpeptidation, and cell membrane interaction/disruption. Oritavancin also has a long half-life, allowing for a single intravenous dose of rather than the standard vacomycin treatment of twice-daily infusions for ten days.